Key result
Telethonin knockdown causes embryonic paralysis and sarcomeric disruption, and while the C-terminus is required for assembly in vitro, in vivo factors can compensate for its truncation or mutation.
The telethonin C-terminus is required for sarcomere assembly in a context-dependent manner, with in vivo factors able to compensate for its truncation or mutation.
Answers are grounded in this paper and cite their sources.
No immediate clinical translation from embryonic models; leaves open context-dependent telethonin roles in human sarcomeric disease.
The N-terminus of telethonin forms a unique structure linking two titin N-termini at the Z-disc. While a specific role for the C-terminus has not been established, several studies indicate it may have a regulatory function. Using a morpholino approach in Xenopus, we show that telethonin knockdown leads to embryonic paralysis, myocyte defects, and sarcomeric disruption. These myopathic defects can be rescued by expressing full-length telethonin mRNA in morpholino background, indicating that telethonin is required for myofibrillogenesis. However, a construct missing C-terminal residues is incapable of rescuing motility or sarcomere assembly in cultured myocytes. We, therefore, tested two additional constructs: one where four C-terminal phosphorylatable residues were mutated to alanines and another where terminal residues were randomly replaced. Data from these experiments support that the telethonin C-terminus is required for assembly, but in a context-dependent manner, indicating that factors and forces present in vivo can compensate for C-terminal truncation or mutation.
No takes yet. Share an insight, caveat, or question.
Sadikot et al. (2010) studied Myocyte defects and sarcomeric disruption. Telethonin knockdown and C-terminal mutation/truncation vs. Full-length telethonin mRNA was evaluated on Sarcomere assembly and motility. Telethonin knockdown causes embryonic paralysis and sarcomeric disruption, and while the C-terminus is required for assembly in vitro, in vivo factors can compensate for its truncation or mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: